436 related articles for article (PubMed ID: 24510515)
61. Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model.
Batten CJ; De Rose R; Wilson KM; Agy MB; Chea S; Stratov I; Montefiori DC; Kent SJ
AIDS Res Hum Retroviruses; 2006 Jun; 22(6):580-8. PubMed ID: 16796533
[TBL] [Abstract][Full Text] [Related]
62. Is an HIV vaccine possible?
Wilson NA; Watkins DI
Braz J Infect Dis; 2009 Aug; 13(4):304-10. PubMed ID: 20231996
[TBL] [Abstract][Full Text] [Related]
63. Anti-HIV and -SIV immunity in the vagina.
Miller CJ; Lü FX
Int Rev Immunol; 2003; 22(1):65-76. PubMed ID: 12710504
[TBL] [Abstract][Full Text] [Related]
64. HIV vaccine development: lessons from the past and promise for the future.
Spearman P
Curr HIV Res; 2003 Jan; 1(1):101-20. PubMed ID: 15043215
[TBL] [Abstract][Full Text] [Related]
65. Mechanisms of protection against simian immunodeficiency virus infection.
Johnson RP
Vaccine; 2002 May; 20(15):1985-7. PubMed ID: 11983259
[TBL] [Abstract][Full Text] [Related]
66. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.
Letvin NL; Schmitz JE; Jordan HL; Seth A; Hirsch VM; Reimann KA; Kuroda MJ
Immunol Rev; 1999 Aug; 170():127-34. PubMed ID: 10566147
[TBL] [Abstract][Full Text] [Related]
67. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
68. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
[TBL] [Abstract][Full Text] [Related]
69. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
70. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIV(KU2) infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail.
Nehete PN; Nehete BP; Hill L; Manuri PR; Baladandayuthapani V; Feng L; Simmons J; Sastry KJ
Virology; 2008 Jan; 370(1):130-41. PubMed ID: 17920095
[TBL] [Abstract][Full Text] [Related]
71. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'.
Vaccine; 1995 Feb; 13(3):295-300. PubMed ID: 7631516
[TBL] [Abstract][Full Text] [Related]
72. Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in burmese rhesus macaques.
Nomura T; Yamamoto H; Shiino T; Takahashi N; Nakane T; Iwamoto N; Ishii H; Tsukamoto T; Kawada M; Matsuoka S; Takeda A; Terahara K; Tsunetsugu-Yokota Y; Iwata-Yoshikawa N; Hasegawa H; Sata T; Naruse TK; Kimura A; Matano T
J Virol; 2012 Jun; 86(12):6481-90. PubMed ID: 22491464
[TBL] [Abstract][Full Text] [Related]
73. Virus inhibition activity of effector memory CD8(+) T cells determines simian immunodeficiency virus load in vaccinated monkeys after vaccine breakthrough infection.
Yamamoto T; Johnson MJ; Price DA; Wolinsky DI; Almeida JR; Petrovas C; Nason M; Yeh WW; Shen L; Roederer M; Rao SS; McDermott AB; Lefebvre F; Nabel GJ; Haddad EK; Letvin NL; Douek DC; Koup RA
J Virol; 2012 May; 86(10):5877-84. PubMed ID: 22419810
[TBL] [Abstract][Full Text] [Related]
74. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Xiao P; Zhao J; Patterson LJ; Brocca-Cofano E; Venzon D; Kozlowski PA; Hidajat R; Demberg T; Robert-Guroff M
J Virol; 2010 Jul; 84(14):7161-73. PubMed ID: 20444898
[TBL] [Abstract][Full Text] [Related]
75. Vaccination with CTL epitopes that escape: an alternative approach to HIV vaccine development?
O'Connor D; Allen T; Watkins DI
Immunol Lett; 2001 Nov; 79(1-2):77-84. PubMed ID: 11595292
[TBL] [Abstract][Full Text] [Related]
76. CD8(+)T-cell-mediated control of HIV-1 and SIV infection.
Freel SA; Saunders KO; Tomaras GD
Immunol Res; 2011 Apr; 49(1-3):135-46. PubMed ID: 21170741
[TBL] [Abstract][Full Text] [Related]
77. Similar abnormalities of idiotype and immunoglobulin light chain expression and of cell-mediated cytotoxicity in HIV-infected humans and simian immunodeficiency virus (SIV)-infected rhesus macaques.
Grant MD; Whaley MD; Mayne A; Hoffmann GW; Ansari AA
Immunol Cell Biol; 1996 Feb; 74(1):38-44. PubMed ID: 8934652
[TBL] [Abstract][Full Text] [Related]
78. Current advances in HIV vaccine preclinical studies using Macaque models.
Liang B; Li H; Li L; Omange RW; Hai Y; Luo M
Vaccine; 2019 Jun; 37(26):3388-3399. PubMed ID: 31088747
[TBL] [Abstract][Full Text] [Related]
79. Vaccine-induced, simian immunodeficiency virus-specific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression.
Engram JC; Dunham RM; Makedonas G; Vanderford TH; Sumpter B; Klatt NR; Ratcliffe SJ; Garg S; Paiardini M; McQuoid M; Altman JD; Staprans SI; Betts MR; Garber DA; Feinberg MB; Silvestri G
J Immunol; 2009 Jul; 183(1):706-17. PubMed ID: 19542473
[TBL] [Abstract][Full Text] [Related]
80. Assessing vaccine effects in repeated low-dose challenge experiments.
Hudgens MG; Gilbert PB
Biometrics; 2009 Dec; 65(4):1223-32. PubMed ID: 19397589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
